Write this down I did a good trade with AAPL

WOW sold my $690 Call Thursday and AAPl went down $14.22 today. May buy that call again Monday. AAPL closed at $667.10 on 19.1 million shares. The three month avg. volume is 15 million shares. Down because of the mapping fiasco. AAPL is still the best company out there............................................................. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ....................................................................................... ACTC down a little at 0.0763 on 4.5 million shares. Needs news........................ ...................................................................................... ...................................................................................... Geron added Susan M. Molineaux and Daniel M. Bradbury to its board of directors. Why? I hope it's to made us shareholders some money. We will see. Geron closed down 3 cents at $1.71 on only 928,853 shares....................................................... ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

AAPL up big, Geron up a little

LOVE AAPL up $16.14 to closed at $681.32 on 21.2 million dollars. The three month avg. volume is 14.6 million shares. I sold my $690 Feb 2013 Call at $45, I bought at $40, made $480. Yea, I should have held it a little longer. But an old investor once said any time you can make money on an option do it. ........................................... .............................................................................................................................................................................. ACTC closed down just a little at 0.0769 on 4.5 million shares. The three month avg. volume is 6 million shares. Need good news............................................ .............................................................................................................................................................................. Geron closed up 2 cent at $1.74 on 1.2 million shares. The three month avg. volume is 1.6 million shares. Waiting for news on the last Phase 2 trials using imetelstats. The first 2 trials were a disaster. The last two trials are on the side effects of imetelstats that might be helpful. Geron said at the end of Dec 2012 will have results. ......................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Geron up, AAPL down

AAPL down, I added 5 big shares at $667 and bought a Feb 2012 $690 Call for $4,000. Will by a few more shares if the share price goes down under $660.................... ...................................................................................... Geron up a little, waiting on news..................................................... ....................................................................................... ACTC flat need some news,.............................................................. .............................................................................................................................................................................. Good luck in this rigged casino,

Geron , ACTC, AAPL all down

Geron closed down 5 cents at $1.70 on 1.2 million shares. The three month avg. is 1.6 million shares. We still around here without any good news........................................................................................................................................................................... ACTC down under 8 cents at 0.0763 on 4.6 million shares. The 3 month avg. is 6.1 million shares. Need goods news or we go lower......................................................................................................................................................................... AAPL $673.53 down $17,25 on 18.5 million shares. The three month avg. volume is 14.4 million shares. Going to buy a few shares Thurs. We could see $650.......................................................................................................................................................................... Good luck in this rigged casino,

AAPL down

AAPL down to close at $690.79 on 22.7 million shares. The three month avg. volume is 14.1 million shares. I think I may buy a few shares or buy a Jan 2014 $800 call, but that's a $5,600 bet................................................................... ACTC down a little under 8 cents at 0.0785 on 6.6 million shares. The three month avg. volume is 6.1 million shares. May add a few thousand shares. Geron closed at $1.75 on 1.5 million shares. Thinking we stay here for a few weeks until there is news, hopefully good............................................... Good luck in this rigged casino,

Geron filed Form 3 with SEC

Geron was up and closed at $1.765 on 2 million shares. The three month avg. volume is 1.6 million shares. Form 3 is for Executive Vice President Andrew J. Grethlein who will be getting 600,000 shares of Geron. Here's his deal: 75,000 shares on March 17, 2013, the rest of the 525,000 shares in a series of 42 equal monthly installments commencing March 17, 2013. That's a good deal and you know he's going to be working hard to get the stock price up by March 17, 2013 and every month after that........................ ACTC closed down a little at 0.08 on 15.6 million shares. The three month avg. volume is 5.9 million shares. Great volume but not great price action. Need more great news .. ........................................................................................ AAPL up over $700 to close at $700.09 on 19.4 million shares. The three month avg. volume is 14 million shares. .......................................................... Good luck in this rigged casino,

ACTC up on good news

The last blog, ACTC got $35 million and that will keep them in business for 2 more years. ACTC closed up a little at 0.0840 on 38.5 million shares. The three month avg. volume is 5.5 million shares. Great volume not much of a price move up. Still need more good news on the Phase1/2 trials ............................................................................................................................................................................................................................................................. Geron was up one cent at $1.71 on 3.8 million shares. The three month avg. is 1.5 million shares. I think we stay around $1.50-$1.80 until we get some good news..................................................................................... AAPL closed down little at $698.70 on 12 million shares. The three month avg. volume is 14 million............................................................................. ........................................................................................ Good luck in this rigged casino,

Good News for ACTC

Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital ................................................................................. Sep 20, 2012 08:30:01 (ET).............................................................. MARLBOROUGH, Mass., Sep 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has entered into a $35 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park Capital") a Chicago-based institutional investor. Upon executing the agreement, Lincoln Park Capital made an initial purchase of $800,000 in common stock from the Company at a purchase price of $0.08 per share. The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC") covering the shares that may be issued to Lincoln Park Capital under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of three years to sell up to an additional $34.2 million of its common stock to Lincoln Park Capital under the terms set forth in the agreement. Proceeds from this transaction will be used to fund the company's clinical activities, including its three ongoing Phase I/II clinical trials for forms of macular degeneration, for development of its other clinical activities, and for general corporate purposes............................................................................... "We are most pleased about this financing agreement, as it has a number of notable benefits for the company," commented Gary Rabin, chairman and CEO of ACT. "Lincoln Park Capital is an excellent partner for us with a great track record and a long-term commitment to the life sciences field. This transaction offers the Company a very cost efficient and readily available form of financing. The $35 million available under the agreement equates to more than two years of funding for the Company, even assuming no other sources of capital. It was a priority for us to complete a new financing by year-end, as we never again want to be in a position to have to go looking for capital from a position of distress or weakness. This agreement strengthens our balance sheet allowing us to focus on advancing our clinical programs, pursuing strategic partnerships, and other long-term objectives.".......................................... Under the terms of the agreement, there are no upper limits to the price that Lincoln Park Capital may pay to purchase the Company's common stock and this transaction in no way impedes or changes the Company's goal of completing a reverse split and national listing. The Company plans to continue pursuing its stated corporate milestones of achieving a national listing and pursuing the optimal corporate partnerships for its programs. The Lincoln Park financing commitment simply strengthens the Company's balance sheet and makes available an additional source of funding. In consideration for entering into the $35 million agreement, the Company has issued additional shares to Lincoln Park Capital as a commitment fee. Under the terms of the agreement, Lincoln Park Capital has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock. Josh Scheinfeld, Managing Member of Lincoln Park Capital, said, "We are very pleased to be entering into this agreement with Advanced Cell Technology. We at Lincoln Park have been following the progression of the Company over the past several years and are excited to be making this investment. We are impressed by the Company's technology and the clinical data that has been published to date." Additional details regarding the financing are included in a Current Report on Form 8-K filed on September 19, 2012 by the Company with the Securities and Exchange Commission. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com .

Geron closed up 16 cents

Well, still no news on why the run up on good volume. Any move up is good. Geron closed at $1.67 on 3.6 million shares. The three month avg. is 1.5 million shares. ............ ACTC was down a little at 0.08 cents on 3.7 million shares. The three month avg. volume is 5.5 million shares. Need some good news.............................................. AAPL up just a little at $702.10 on 11.6 million shares. Volume going down could mean price as peaked for now................................................................ Good luck in this rigged casino,

Geron up 20 cent on 3+ million share

Once burned twice shy, baby. All the signs say great news is coming soon, just like the last run. I'm just going to wait, have 6,000+ shares not covered so I'm getting a good ride from this run. Just hope it's some thing great and that's all it is hope.................................................................................... Good luck in this rigged casino,

Geron up 13 cent on good volume

Geron is at $1.67 on over 2.2 million shares. I can't find anything for the price increase. With Geron there is always doubt but as long as they're in business there's a chance. I have 40 covered calls [that's 4,000 shares] at $2, half for Oct and half for Mar 2013. Hoping for good news after Oct 19th. Good luck in this rigged casino,

ACTC up Geron up AAPL over 700

Great day! Geron hired new attorneys for the Patent case, so maybe they will appeal. Geron closed up 11 cents at $1.54 on almost 3 million shares. The three month avg. volume is 1.5 million shares. I like the volume with the price, is there some good news coming. With Geron there is always doubt but as long as they're in business there's a chance. ACTC up over 8 cents to close at 0.081 on 6.2 million shares. The three month avg. volume is 5.5 million shares. Hoping for some good news soon. AAPL up over $700 YEA BABY, closed at $701.91. Good luck in this rigged casino,

ACTC down on settlement

ACTC was down under 8 cent at 0.078 on 15 million shares. The news was a settlement with Alpha Capital of $500,000 which was paid with 34,285,714 shares. I may buy a few more shares. Geron hired Adrew J. Grethein PhD, he will oversee the Company's manufacturing and quality functions. Let's hope thet are seeing some positive results on GRN1005. Geron closed up 2 cents at $1.43 on 1.5 million shares. AAPL up again closing in on $700. It closed at 699.78 on 13.7 million shares. The three month avg. volume is 14 million shares. We'll hit $750 soon. Good good in this rigged casino,

ACTC can remove embryonic stem-cell without destroying

ACT uses an embryonic stem-cell-removal technique that doesn’t destroy anything: It removes a single cell from embryos that are in the eight-cell stage--in other words, extremely early on. It’s identical to what’s done in in-vitro fertilization clinic for genetic testing of diseases like Tay-Sachs and Huntington’s Disease. "It’s a non-destructive, non-harmful method of extracting these cells and creating embryonic stem cells. There are thousands of babies born every year having this exact kind of genetic testing done," says ACT CEO Gary Rabin.
ACTC closed down a little at 0.082 on 8.4 million shares. The three month avg. volume is 5.2 million shares.

AAPL closed up $8.30 at $691.28 on 21.4 million shares. The three month avg. volume is 14 million shares.

Poor, poor Geron closed down just a little at $1.41 on 2.6 million shares. The three month avg. volume is 1,440,810 shares.

Good luck in this rigged casino,

Geron selling the HESC portfolio very soon

That's the rumor on Yahoo Message Board. Some folks are says that's why the share price is going up. I don't think Geron will get much money up front. Chip the CEO said so a while back. Geron closed up 8 1/2 cents at $1.415 on 3.7 million shares. The three month avg. volume is 1,351,790 shares. I like the volume, we could go up to $1.75, but I think more bad news is coming.

ACTC closed up a little at 0.0855 on 3.5 million shares. The three month avg. volume is 5.1 million shares.

AAPL was up $13.19 to close at $682.98 on 21.3 million shares. The three month avg. volume is 13.7 million shares.

Fed's stimulus move ignites Wall Street. That's the headline, and we will go higher and if the economy does not improve soon 3-6 months we will drop like a stone.

Good luck in this rigged casino,

Dead cat bounce for Geron?

Maybe!  I sold 20  $2 Mar 2013 covered calls for 20 cents will lose $2 thousand if there are called home in Mar 2013. Geron up to $1.40 on good volume. Again there's a small chance the last two Imeteltat trials may have good results just because it's betting on the side effects of the drug not the effect of the drug. The GRN1005 will make or break this company. Again I will keep 3-5 thousand shares until the results are known. I have sold 50 covered calls [that's 5 thousands shares] leaving me about 8 thousand shares not covered.

Good luck in this rigged casino,

Geron up AAPL up

Dead cat bounce for Geron? Maybe. With only GRN1005 and maybe a small, very small chance that the last two trial with imetelstat may work I can't put much hope in this company. So I sold 1000 shares at $1.30 for a $400 loss and sold 10 $1 covered calls for Mar 2013 for 55 cents, that would be a $1500 loss. I'm still going to keep 3-5 thousand shares till the GRN1005 trials are over and results are known. I can't believe a Geron could be 100% wrong on everything they have done. Even a blind squirrel finds a nut once in a while.
Geron was up 7 cents to close at $1.33 on 2.8 million shares. The three month avg. volume is 1.3 million shares.
Remember the last two imetelstat trial are going for the side effects of imetelstat that helps lower the red blood count, [I may have that a little wrong but it's the side effect of imetelstat, Geron is hoping that will work].

ACTC,  I thought was going to move up, but it closed down a little at 0.0845 on 9.4 million shares. The three month avg volume is 5 million shares. ACTC is the future in bio-tech.

AAPL iPhone 5 and it's up 9.20 to closed at $669.79 on 24.7 million shares. We go higher.

Good luck in this rigged casino,

Geron down and ACTC up over 9

Geron was down only two cent to close at $1.26 on 4.1 million shares. I sold 1000 shares at $1.26, will sell more and will sell some covered calls at $1.00. It's dark days ahead for Geron. I was surprised it didn't close lower. New 52 week low $1.23.

ACTC was up over 9 cents at 0.0914 on 15 million shares. I think we go higher.

Good luck in this rigged casino,

Geron down 55% closed at $1.28

The worst thing that could have happened,,,,,,,HAPPENED. The people being treated with the imetelstate were dying sooner then the people not taking imetelstate. It can't get worse than that. So Geron stopped the breast cancer trial and they stated the small cell lung cancer trial was not showing much improvement. So that means only two trials left using imetelstate, only a miracle will save these trials. Now that leave the two GRN1005 trials that will have results sometime in the 2Q of 2013. Maybe that will save Geron. My confidence in Geron is totally shot. I will be slowly selling my shares down to around 3,000 shares.
Geron closed down 55.86% at $1.28 on 19.5 million shares. The three month avg. volume is 976,773 shares.

Good luck in this rigged casino,

Disaster of the highest order for GERON

Geron Corp. (GERN, Trade ) shares fell 51%. The biotech firm said Monday that it's discontinuing its Phase II study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival was shorter than the comparison treatment.  I'm working tell I'm 70 or till I drop dead. Cry me a river.
DISASTER, DISASTER, DISASTER, DISASTER.

GOOD LUCK IN THIS RIGGED CASINO,

ACTC Sept 10th webcast

ACTC chairman and CEO Gary Rabin will be presenting at the 14^th Annual Rodman & Renshaw Global Investment Conference, Sept. 9-11 in New York. Mr. Rabin’s presentation will take place on Monday, Sept. 10, at 12:05 p.m. EDT, at the Waldorf Astoria. We need some good news.


Good luck in this rigged casino,

Geron new high again

Geron closed up 6 cents at $2.90 on 1.7 million shares. The new 52 week high is $2.99. The three month avg. volume is 967,411shares. What does the future hold for Geron? Here's my vision. Geron continues to $3.75-4.30. When Phase 2 oncology test results are announced in 4th quarter. With good news Geron spikes to $5.50-7.00. With good news in 1st quarter of 2013 on GRN1005. Geron spikes to $8-10. Shortly thereafter Geron is sold for $14-20.  Just a dream.

AAPL up again to close at $680.50 on 11.6 million shares. The three month avg. volume is 13.5 million shares.

ACTC closed up a little at 0.0828 on 3.1 million shares. The three month avg. volume is 4.7 million shares.

Good luck in this rigged casino,

Geron new high again

Geron was up to $2.98 so far today, which is a new 52 week high. Geron's around $2.95 now. The volume is not great, under 800,000 shares so far.  We're up from $1.71 on Aug 17th. to almost $3 today. Now think what will happen if the Phase two results are good. A guess would be a run to $6, maybe more and if Geron gets a partner, I can see $10. Down the road $20 with more good results. If the Phase two results are poor Geron trials under a $1. It's a big reward if I'm right. If I'm wrong I'll be crying me a river.

Good luck in this rigged casino,

ACTC to Present Sept 10th

MARLBOROUGH, Mass., Sep 07, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that ACT's chairman and CEO Gary Rabin will be presenting at the 14th Annual Rodman & Renshaw Global Investment Conference, Sept. 9-11 in New York. Mr. Rabin's presentation will take place on Monday, Sept. 10, at 12:05 p.m. EDT, at the Waldorf Astoria.
The presentation will be webcast live (link here) and the presentation slide deck will be available on the conference presentations section of the ACT website.
Should move share price up.

Good luck in this rigged casino,

Geron New 52 Week High

Geron closed up at $2.845 the new 52 week high is $2.88 on over 2 million shares. The three month avg. is 967,411 shares. Volume has been good and we keep going up. $3.00+  Next stop. If we keep going up on good volume I would say the Phase two trials are going to have good results and it's known by a few people who are buying.

ACTC closed down just a little 0.8018 on 2.5 million shares. The three month avg. volume is 4.8 million shares.

AAPL closed up at $676.27 on 14 million shares. The three month avg. volume is 13.6 million shares.

Good luck in this rigged casino,

Geron's CEO Chip was good

Geron's CEO "Chip" give a good presentation at the Stifiel Nicolaus Healthcare Conference. You can listen to and watch at there website. Geron closed down at $2.73 on 1.7 million shares. We also hit a new 52 week high of $2.83.  The three month  avg. volume is 933,738 shares. What I think from listening to "Chip" is the Breast Cancer phase two trial are going well [having good results the patients are living longer] because they where going to report results at the end of Dec 2012 and had to move it to 1st Q of 2013.  I think we will still go a little lower before Dec 2012. If it all works out in Geron's favor we will hit $5 by 2013. If not we will be under $2.

Good luck in this rigged casino,

Geron new 52 week high

Geron closed at $2.79 up three cents and hit a new 52 week high of $2.82. The volume was 1.6 million shares. The three month avg. volume is 908,797.  Geron's CEO "Chip" will speak Sept 5th Wed at 10:55 AM.  Hoping for something new.

AAPL up to close at $674.97 on 13 million shares. The three month avg. volume is 13.6 million shares.

ACTC closed up a little at 0.0829 on 3.9 million shares. The three month avg. 4.8 million shares.

Good luck in this rigged casino,

Seeking Alpha on Geron today

Geron (GERN) - Imetelstat: Following its consolidation in the oncology field, Geron is currently conducting four Phase II studies with Imetelstat, a first-in-class telomerase inhibitor targeted at solid tumors and hematological malignancies. One of Imetelstat's main advantages, which is derived from its mode of action, is that it could be suitable for treating a wide varaiety of tumors. Should results from the Phase II studies, expected during 2013, will prove efficacy this drug will become a strong candidate for a licensing deal.
The Phase two trials have to be good or Geron is done.

Good luck in this rigged casino,

ACTC Dr. Lanza to Deliver Opening Speech 4th Annual

ACT's Chief Scientific Officer Dr. Robert Lanza to Deliver Opening Keynote Address at 4th Annual Stem Cell Symposium in Singapore

Sep 4, 2012 08:30:02 (ET)

MARLBOROUGH, Mass., Sep 04, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the opening Keynote Speech at the 4th Annual Stem Cell Symposium 2012, being held in Singapore, September 6-7. Dr. Lanza's presentation is titled "Pluripotent Stem Cells -- From Benchtop to Clinic."
With the theme, "Stem Cell Based Therapy," the symposium will have a particular focus on clinical trials and industrial application of stem cells. Sponsored by Stem Cell Society of Singapore (SCSS), the conference will include scientific presentations from key contributors from academic, clinical, and commercial organizations who are translating basic research on stem cells into therapeutics, with a focus on applying engineering technologies to provide medical solutions.
In their opening statement, the organizers state, "We are all keeping our 'fingers crossed' for ACT's success, which will also bring a big boost to the stem cell community."
Other topics of the conference include human induced pluripotent stem cells (hiPSCs), drug screening, adult and cancer stem cells, and stem cell therapies emerging from Asia, with presentations from Indian, Korean and Japanese regenerative medicine companies. There will also be a joint session with the International Society for Cellular Therapy (ISCT) covering important issues concerning the commercialization of stem cells, and addressing issues such as reimbursement, manufacturing, characterization, and clinical implementation issues unique to cell therapies.

Geron's CEO "Chip" will speak Wed at 10:55AM it will be webcast, should move the share price up or down. Geron has had a great run from $1.71 on Aug 17th to $2.76 today.

Good luck in this rigged casino,

Geron good run, but to soon

Biotech Geron (Nasdaq: GERN ) was perhaps the one stock rising for a reason, as an analyst offered a positive outlook on the cancer therapies it's developing, but the stock has been on the move for awhile now (up 60% over the past month) after a positive review two weeks ago on Seeking Alpha. I said at the time the treatments hold a lot of promise, but the results of midstage trials have some time to go before we see the actual outcome, so the spike in its shares now seems a bit premature. I'd say the same for the current run-up based on the rosy view offered up by the Wall Street analyst.

Good luck in this rigged casino,